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Differential impact of drugs on the outcome of ETV6-RUNX1
positive childhood B-cell precursor acute lymphoblastic
leukaemia: results of the EORTC CLG 58881 and 58951 trials
Leukemia (2018) 32, 244–248; doi:10.1038/leu.2017.289
In childhood B-cell precursor acute lymphoblastic leukaemias
(BCP-ALL), the presence of an ETV6-RUNX1 fusion transcript
deﬁnes one of the most prevalent genetic subgroups, together
with the high hyperdiploidy (HeH) ALL. Although ETV6-RUNX1pos
ALLs are associated with favourable outcome, their proper
treatment strategies remain debatable, some groups suggesting
crucial impact of upfront intensive treatment1 while others favour
low-intensity antimetabolite-based therapy.2
To address this question, we evaluated the long-term prog-
nostic and predictive value of ETV6-RUNX1 in BCR-ABL1 negative
de novo BCP-ALL children (1–17 years old) treated in the European
Organisation for Research and Treatment of Cancer (EORTC)
studies 58881, opened between January 1989 and November
19983 (n= 1692) and 58951 opened between December 1998 and
August 20084,5 (n= 1602). Particular attention was given to the
effects of the randomized treatments (Supplementary Figures S1
and S2) in the ETV6-RUNX1pos subgroup as compared with those
observed in the HeH and ‘Others’ BCP-ALL subgroups, in order to
reveal speciﬁc drug response proﬁles related to distinct oncogenic
process.
In total, 1887 BCP-ALL were screened for the presence of ETV6-
RUNX1: 394 in study 58881 and 1493 in study 58951. In both
studies, clinical features and outcome were similar to those of
patients not screened (Supplementary Tables S1 and S2).
ETV6-RUNX1 was evidenced in 488/1887 patients (25.9%) and
HeH in 595/1887 patients (31.5%). The 804 (42.6%) remaining
patients (‘Others’) had others or unknown genetic abnormalities
(Supplementary Figure S3). Clinical and biological features of
patients according to the ETV6-RUNX1 status and by genetic
subgroups are presented in Supplementary Tables S3 and S4.
The median follow-up was 11.7 years and 6.7 years for study
58881 and 58951, respectively.
The 10-year event-free survival (EFS) rate was globally improved
in study 58951 as compared with study 58881 (82.7% vs 73.1%). In
both studies, the 10-year EFS was signiﬁcantly higher in the ETV6-
RUNX1pos group than in the ETV6-RUNX1neg group (Table 1 and
Supplementary Figure S4). ETV6-RUNX1pos patients had also a
signiﬁcantly higher 10-year overall survival (OS) rate (93.3 vs 82.0%
in 58881, 95.3 vs 87.8% in 58951; Supplementary Figures S5
and S6).
The 10-year EFS of the ETV6-RUNX1pos group was similar to that
of the HeH group, but drastically superior to the one of the
‘Others’ subgroup (Figure 1).
Noteworthy, in the ETV6-RUNX1pos group, EFS events mostly
occurred after the end of the maintenance therapy, with very few
events before, and virtually no event after 6 years from diagnosis.
In both studies, the higher EFS of the ETV6-RUNX1pos group was
mainly due to lower rates of induction failures and relapses and to
treatment-related mortality rates below 1.5% (Supplementary
Tables S3 and S4).
Erwinia-asparaginase (ASNase) vs E. coli-ASNase for all risk groups in
study 58881,6 and prolonged vs classical number of ASNase
administrations for non-very-high-risk (VHR) patients in study
589517
In ETV6-RUNX1pos patients, the exact role of ASNase in vivo
remains unclear. In vitro analyses have revealed that ETV6-
RUNX1pos cells are exquisitely sensitive to ASNase but similar
outcomes have been described with8 or without9 intensive
ASNase administration.
In study 58881, 94 patients were randomized for E. coli-ASNase
(n= 46) or Erwinia-ASNase (n= 48), and 300 additional patients
received E. coli-ASNase (Table 1 and Supplementary Table S5). The
overall improvement of the 10-year EFS with E. coli-ASNase as
Accepted article preview online 19 September 2017; advance online publication, 24 october 2017
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compared with Erwinia-ASNase was approximately 10%, as in the
main publication,6 and around 33% in the HeH group. In contrast,
in the ETV6-RUNX1pos group, the 10-year EFS improvement was
limited (3.7%). This is in line with results of the DFCI 95-01 study,
showing no signiﬁcant difference regarding EFS in 77 ETV6-
RUNX1pos patients treated with either E. coli- or Erwinia-ASNase.8
In study 58951, 1229 non-VHR patients were randomized for
prolonged (‘long-ASNase’) vs classical (‘short-ASNase’) courses of
asparaginase during consolidation/late intensiﬁcation7 (Table 1
and Supplementary Table S5). Overall, the 10-year disease-free
survival (DFS) was 87.0% in the ‘long-ASNase’ arm and 83.6% in
the ‘short-ASNase’ arm. In the ETV6-RUNX1pos subgroup (n= 333),
the impact of ‘long-ASNase’ was weak with a 10-year DFS rate of
94.8% in the ‘long-ASNase’ vs 91.2% in the ‘short-ASNase’ arm. In
the HeH subgroup, ‘long-ASNase’ did not prolong the DFS as
compared with ‘short-ASNase’. St Jude obtained outstanding
results (5-year EFS of 96.8%) in ETV6-RUNX1pos patients treated
with the Total XV regimen through intensiﬁed use of ASNase,
vincristine and dexamethasone (DEX).10 However, our results,
while limited by the relatively low number of patients suggest that
the beneﬁt of ASNase intensiﬁcation is low in ETV6-RUNX1pos
patients and that similar results can be reached without ASNase
intensiﬁcation.
Prednisone (PRED) (60 mg/m2/day) vs DEX (6 mg/m2/day) during
induction in study 589515
In the present analysis, the overall difference between DEX and
PRED regarding EFS was not signiﬁcant, as in the whole cohort
analysis.5 Similarly, no difference regarding EFS was observed in
ETV6-RUNX1neg patients, or in the HeH and ‘Others’ subgroups
considered separately (Table 1 and Supplementary Figure S7A).
By contrast, ETV6-RUNX1 status had a signiﬁcant impact (test of
heterogeneity: P= 0.05) on the treatment difference (Table 1 and
Supplementary Figure S7A). In the ETV6-RUNX1pos subgroup, the
10-year EFS was higher in the DEX group as compared with PRED
(95 vs 87.2%). This difference remained practically unchanged
when adjusting by sex, NCI risk group and EORTC risk group (VHR
vs non-VHR) by using a Cox model (HR = 0.47, 99% CI = 0.17–1.30;
two-sided Wald test: P= 0.055). The 10-year OS was comparable in
both arms (96.3 vs 94.5%, HR= 0.84, 99% CI = 0.21–3.37; two-sided
log-rank test: P = 0.74).
A possible role for DEX in ETV6-RUNX1pos patients had already
been suggested by the St Jude group, who obtained outstanding
results with DEX pulses during maintenance therapy.10 In the
randomized trial AIEOP-BFM ALL 2000,11 higher 5-year EFS rates
were observed in the ETV6-RUNX1pos subgroup treated with DEX
10 mg/m2 in induction when compared with PRED 60 mg/m2, but
this advantage did not translate into higher 5-year OS. In study
58951, the improvement in ETV6-RUNX1pos patients regarding EFS
did not either lead to an improvement in OS, since the majority of
relapses occurred after the end of the maintenance therapy, and
could then be salvaged with second-line therapies. However,
toxicities of salvage therapies have to be balanced with those of
ﬁrst-line treatments and DEX at 6 mg/m2 did not increase the
incidence of infections and osteonecrosis in study 58951.5
Furthermore, the majority of ETV6-RUNX1pos patients, being less
than 10-year-old, are at low risk of osteonecrosis.
Monthly intravenous (i.v.) 6-mercaptopurine (6-MP) (1 g/m2) vs no
i.v. 6-MP during maintenance therapy for non-high-risk patients in
study 5888112
A total of 200 patients were randomized for the i.v. 6-MP question
(Supplementary Table S5).12 The addition of i.v. 6-MP was
associated with a signiﬁcantly lower 10-year DFS (two-sided log-
rank test: P= 0.03) (Table 1).
Strikingly, in ETV6-RUNX1pos patients, the 10-year DFS was 71.4%
in the i.v. 6-MP group vs 100% in the classic maintenance group,
whereas the treatment difference was less marked in the HeH and
‘Others’ subgroups (Table 1 and Supplementary Figure S7B). ETV6-
RUNX1pos patients treated with classic maintenance outside the
randomization (n= 47) had a 10-year DFS from CR of 82.7%.
The addition of i.v. 6-MP was previously shown to lead to
signiﬁcantly worse outcome in study 58881.12 The present analysis
further showed that the deleterious effect of i.v. 6-MP was mainly
observed in the ETV6-RUNX1pos subgroup. ETV6-RUNX1pos relapses
have been suggested to arise from quiescent pre-leukaemic
clones persisting after eradication of the overt leukaemia cells, and
prolonged exposure to 6-MP/methotrexate during maintenance
therapy increases the risk of second cancers.13 Thus, i.v. 6-MP
might have fostered the oncogenic process, leading to ‘secondary
leukaemia’ relapses in ETV6-RUNX1pos patients.
Alternatively, the deleterious effect of i.v. 6-MP could be related
to a speciﬁc susceptibility of ETV6-RUNX1pos cells to antileukaemic
agents that inhibit de novo purine synthesis. High-doses of 6-MP
result in a preferential increase in methylated metabolites via thio-
purine methyl-transferase as compared with cytotoxic thioguanine
nucleotides via hypoxanthine-guanine phosphoribosyltransferase.
ETV6-RUNX1pos cells express low levels of hypoxanthine-guanine
phosphoribosyltransferase as compared with other ALL
subgroups.14 High-dose 6-MP could thus result in a higher
production of methylated metabolites, especially in ETV6-
RUNX1pos cells. Because methylated metabolites inactivate de
novo purine synthesis,15 critical for cell progression, they could
induce cell dormancy, protecting ETV6-RUNX1pos cells from
Figure 1. Kaplan–Meier curves of event-free survival by genetic
subgroup (ETV6-RUNX1pos, HeH or ‘Others’) in EORTC study (a) 58881
and (b) 58951.
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maintenance therapy. At completion of maintenance therapy,
quiescent leukaemia cells could re-enter cell cycle and lead to
relapse, which is consistent with the high rate of relapses
occurring after the end of maintenance in ETV6-RUNX1pos patients
randomized in the i.v. 6-MP arm.
Vincristine-corticosteroid pulses vs no pulses during maintenance
therapy for average risk (AR) patients in study 589514
A total of 301 patients were randomly assigned for this question
(Supplementary Table S5).
Overall, the 10-year DFS was higher in the pulse arm, as
previously reported,4 but the difference was not signiﬁcant in this
subanalysis (Table 1).
In the HeH subgroup, the 10-year DFS was approximately 90%
in both arms. In the ‘Others’ subgroup, the pulses improved the
10-year DFS by approximately 11%, while ETV6-RUNX1pos patients
had similar outstanding outcomes in both arms (Table 1).
Noteworthy, these latter AR patients treated with E. coli-ASNase
had already outstanding outcome with a 10-year DFS rate of
96.1%. If these data are conﬁrmed, vincristine-corticosteroid
pulses could be avoided in this speciﬁc subgroup.
In conclusion, our observations identiﬁed in vivo treatment
sensitivities, which were speciﬁc to the ETV6-RUNX1pos subgroup:
the beneﬁt of DEX instead of prednisone in induction, the limited
role of asparginase intensiﬁcation and the importance of low-
intensity maintenance therapy. These results stress the beneﬁt of
analysing homogeneous oncogenetic subgroups when comparing
different therapeutic schemes.
Of course, interpretation of such retrospective subgroup
analyses needs to be done with caution as they were unplanned
in the study design, so they were underpowered. Such ﬁndings
are exploratory in nature, and require conﬁrmation in other
studies.
In future randomized studies one should aim not only to
evaluate the overall treatment effect but also the possible
heterogeneity of treatment difference according to the ALL
subgroups.
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